[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26928-26929]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07941]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on January 5, 2024, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing (1) 
the identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture as of the date of this filing are: AATec Medical GmbH, 
M[uuml]nchen, GERMANY; ASELL LLC, Owings Mills, MD; Access to Advanced 
Health Institute, Seattle, WA; Adaptive Phage Therapeutics, Inc., 
Gaithersburg, MD; Advanced BioScience Laboratories, Inc., Rockville, 
MD; Aerium Therapeutics, Inc., Boston, MA; Alamgir Research, Inc. dba 
ARIScience, Wayland, MA; Alchem Laboratories Corp., Alachua, FL; 
Alentic Microscience, Inc., Halifax, Nova Scotia, CANADA; Altec, Inc., 
Natick, MA; Antiviral Technologies LLC, Dallas, TX; ApiJect Systems 
America, Inc., Stamford, CT; Applied Materials, Inc., Santa Clara, CA; 
Apriori Bio, Inc., Cambridge, MA; Aridis Pharmaceuticals, Inc., Los 
Gatos, CA; AstraZeneca Pharmaceuticals LP, Wilmington, DE; Atea 
Pharmaceuticals, Inc., Boston, MA; Attogene, Austin, TX; BCG Federal 
Corp., Washington, DC; BioFire Defense LLC, Salt Lake City, UT; 
BioTechnique LLC, York, PA; BiotechPharma Corp., Severna Park, MD; 
Bioxytran, Dedham, MA; Boston Engineering Corp., Waltham, MA; 
BrainScope Company, Inc., Chevy Chase, MD; Brimrose Technology 
Corporation, Sparks, MD; BugSeq, Inc., San Francisco, CA; CAMRIS 
International, Bethesda, MD; CASTLEVAX, Inc., New York, NY; CUBRC, 
Inc., Buffalo, NY; Care Access Research LLC, Boston, MA; Cayuga 
Biotech, New York, NY; Cepheid, Sunnyvale, CA; ChromoLogic, Monrovia, 
CA; Civica, Inc., Lehi, UT; Clarivate Analytics (US) LLC, Ann Arbor, 
MI; CliniOps, Inc., Fremont, CA; Cocrystal Pharma, Inc., Miami, FL; 
Codagenix, Inc., Farmingdale, NY; Concord Medical Technology Corp., 
Grand Forks, ND; Critical Innovations LLC, Lawndale, CA; Curia Global, 
Inc., Albany, NY; CyanVac LLC, Athens, GA; Delta Development Team, 
Inc., Tucson, AZ; Detect, Inc., Guilford, CT; Duke University, Durham, 
NC; Dyadic International, Inc., Jupiter, FL; Dynavax Technologies 
Corp., Emeryville, CA; Eagle Health Analytics LLC, San Antonio, TX; 
Endpoint Health, Palo Alto, CA; Esparza Pest Control and Eco-Logic 
Systems, Inc., Edinburg, TX; EverGlade Consulting LLC, Charleston, SC; 
Everest Consulting Group, Bethesda, MD; ExeVir Bio, Zwijnaarde, 
BELGIUM; FHI Clinical, Durham, NC; First Line Technology LLC, 
Fredericksburg, VA; Foamtec International Co., Ltd., Waco, TX; Foothill 
Scientific Associates, CA; GRIP Molecular Technologies, Inc., St. Paul, 
MN; GenVault, West Deptford, NJ; Generate Biomedicines, Inc., 
Somerville, MA; GeoVax, Inc., Smyrna, GA; Ginkgo Bioworks, Inc., 
Boston, MA; Global Resonance Technologies LLC, Shelburne, VT; Gritstone 
bio, Inc., Emeryville, CA; Healthtrek LLC, Tampa, FL; Hexagon Bio, 
Inc., Menlo Park, CA; ICON Government and Public Health Solutions, 
Inc., Blue Bell, PA; Immune Biosolutions, Sherbrooke, CANADA; 
ImmunityBio, Inc., Culver City, MN; Immuron, Ltd., Blackburn North, 
AUSTRALIA; Inflammatix, Inc., Sunnyvale, CA; Integrated Pharma 
Services, Frederick, MD; Invivyd, Inc., Waltham, MA; Irving Burton 
Associates LLC, Silver Spring, MD; Island Pharmaceuticals, Ltd., 
Camberwell, AUSTRALIA; Iuventis Technologies, Inc., Olean, NY; JEEVA 
INFORMATICS

[[Page 26929]]

SOLUTIONS, Inc., Manassas, VA; Jubilant HollisterStier, Spokane, WA; 
Jurata Thin Film, Inc., Houston, TX; K2 Biolabs, Inc., Houston, TX; 
LaCire LLC, Alexandria, VA; Latham BioPharm Group LLC, Elkridge, MD; 
Leidos, Reston, VA; Lex Diagnostics, Ltd., Melbourn, UNITED KINGDOM; 
Locus Biosciences, Morrisville, NC; Longhorn Vaccines and Diagnostics 
LLC, Bethesda, MD; Luna Labs USA LLC, Charlottesville, VA; Lungpacer 
Medical USA, Inc., Exton, PA; MMV Medicines for Malaria Venture, 
Geneva, SWITZERLAND; MRIGlobal, Gaithersburg, MD; Mapp 
Biopharmaceutical, Inc., San Diego, CA; Maravai Lifesciences, San 
Diego, CA; Maxwell Biosciences, Inc., Austin, TX; MeMed, Tirat Carmel, 
ISRAEL; Medigen, Inc, Frederick, MD; Meletios Therapeutics, Paris, 
FRANCE; Micron Biomedical, Inc., Atlanta, GA; Military Health Research 
Foundation, Inc., Laurel, MD; Mission Pharmacal Company, San Antonio, 
TX; Model Medicines, Inc., La Jolla, CA; ModernaTx, Cambridge, MA; 
Molecular Technologies Laboratories LLC dba InfinixBio, Galena, OH; 
NextBeam LLC, North Sioux City, SD; Ocugen, Inc., Malvern, PA; Ocyonbio 
LLC, Aguadilla, PUERTO RICO; OneBreath, Inc., Palo Alto, CA; Otter Cove 
Solutions LLC, Gaithersburg, MD; PPD Development LP, Wilmington, NC; 
Pacto Medical, Inc., Middletown, DE; Parallel Biosciences, Inc., 
Cambridge, MA; Peptilogics, Inc., Pittsburgh, PA; Pfizer, Inc., New 
York, NY; Phare Bio, Boston, MA; Pharm-Olam LLC dba Allucent, Cary, NC; 
PharmaJet, Inc., Golden, CO; Phlow Corp., Richmond, VA; PopVax Private 
Limited, Mumbai City, INDIA; QUZE Pharmaceuticals, Inc., Windsor, CO; 
Rajant Health, Inc., Malvern, PA; Regis Technologies, Inc., Morton 
Grove, IL; Research Lifecycle Solutions LLC, Franklin, TN; Resilience 
Government Services, Inc., Alachua, FL; Riya Interactive Inc., Hawthorn 
Woods, IL; Ronawk, Inc., Overland Park, KS; Rubix Strategies LLC dba 
Rubix LS, Lawrence, MA; SEQENS, Devens, MA; SRI International, Menlo 
Park, CA; Safi Biotherapeutics, Inc., Cambridge, MA; Sanofi Pasteur, 
Inc., Swiftwater, PA; Schrodinger LLC, Portland, OR; Shabas Solutions 
LLC, Fairfax, VA; Sibel Health, Inc., Chicago, IL; Signature Science 
LLC, Austin, TX; Swaza Inc., Mountain View, CA; Synedgen, Inc., 
Claremont, CA; TFF Pharmaceuticals, Inc., Fort Worth, TX; Texas 
Biomedical Research Institute, San Antonio, TX; The Conafay Group, 
Washington, DC; The Geneva Foundation, Tacoma, WA; The Henry M. Jackson 
Foundation for the Advancement of Military Medicine, Bethesda, MD; The 
Medical Countermeasures Coalition, Washington, DC; The Tiny Cargo 
Company, Roanoke, VA; ThirdLaw Molecular LLC, Blue Bell, PA; TrippBio, 
Inc., Jacksonville, FL; Uh-Oh Labs Inc. dba Scout, Santa Clara, CA; 
Univox Technical Solutions DBA Univox LLC, Tijeras, NM; Valneva Austria 
GmbH, Vienna, AUSTRIA; Vanderbilt Vaccine Center, Nashville, TN; Varda 
Space Industries, Inc., El Segundo, CA; Vaxart, Inc., South San 
Francisco, CA; Vaxess Technologies, Inc., Cambridge, MA; Vaxxas, Inc., 
Cambridge, MA; Vibrent Health, Fairfax, VA; Vir Biotechnologies, San 
Francisco, CA; Viti Pharmaceuticals, Miami, FL; Wizbiosolutions, Inc., 
Vienna, VA.
    Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the general 
area of RRPV's planned activities are to accelerate Medical 
Countermeasure (MCM) technology development to address evolving needs 
including pandemic influenza, emerging infectious diseases, and other 
biological threats. It will accelerate partnering, improve 
responsiveness, and meet expanding demand to develop future MCM needs. 
It will advance health security, enhance preparedness, and enable a 
rapid response to future pandemic or high consequence biological 
threats.

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07941 Filed 4-15-24; 8:45 am]
BILLING CODE P